Purine

Purine

SCHEMBL1963684

COc1ccc(OC)c(Cc2nc3c(N)nc(N)nc3[nH]2)c1.c1ncc2[nH]cnc2n1

nearest known ligand 0.45

Full drug profile on Sugi Atlas →

Predicted protein targets (top 8)

geneUniProtsupporting neighboursconfidence
DHFR P00374 10/20 0.45
HSP90AA1 P07900 1/20 0.45
HSP90AB1 P08238 1/20 0.45
BRAF P15056 1/20 0.42
MAP3K5 Q99683 1/20 0.42
PDGFRB P09619 1/20 0.39
FLT1 P17948 1/20 0.39
KDR P35968 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Purine SCHEMBL1963679 0.88 DHFR (0.44) DHFRHSP90AA1HSP90AB1PDGFRBFLT1
SCHEMBL1966500 0.84 HSP90AA1 (0.56) DHFRHSP90AA1HSP90AB1PDGFRBFLT1
SCHEMBL30583198 0.75 HSP90AA1 (0.69) DHFRHSP90AA1HSP90AB1PDGFRBFLT1
SCHEMBL4310551 0.75 HSP90AA1 (0.69) DHFRHSP90AA1HSP90AB1PDGFRBFLT1
SCHEMBL1855267 0.68 DHFR (0.53) DHFRKDR
Trimetrexate SCHEMBL5981602 0.66 DHFR (0.71) DHFR
SCHEMBL4852808 0.65 DHFR (0.52) DHFR
SCHEMBL2947301 0.65 PDE2A (0.48) KDR
SCHEMBL13607782 0.64 HSP90AA1 (0.47) DHFRHSP90AA1HSP90AB1PDGFRBFLT1
SCHEMBL4057239 0.64 SMN1; SMN2 (0.61) DHFRHSP90AA1HSP90AB1PDGFRBFLT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2336133-A1 Purine analogs having HSP90-inhibiting activity Conforma Therapeutics Corporation (US) 2011-06-22 EP disclosed
EP-1962863-A2 ORALLY ACTIVE PURINE-BASED INHIBITORS OF HEAT SHOCK PROTEIN 90 Conforma Therapeutics Corporation (US) 2008-09-03 EP disclosed
US-20080125446-A1 Purine analogs having HSP90-inhibiting activity CONFORMA THERAPEUTICS CORPORATION 2008-05-29 US disclosed
US-7241890-B2 Purine analogs having HSP90-inhibiting activity CONFORMA THERAPEUTICS CORPORATION (US) 2007-07-10 US disclosed
WO-2007075572-A2 ORALLY ACTIVE PURINE-BASED INHIBITORS OF HEAT SHOCK PROTEIN 90 CONFORMA THERAPEUTICS CORPORATION (US) 2007-07-05 WO disclosed
US-20070129334-A1 Orally Active Purine-Based Inhibitors of Heat Shock Protein 90 CONFORMA THERAPEUTICS CORPORATION (US) 2007-06-07 US disclosed
US-20050049263-A1 Purine analogs having hsp90-inhibiting activity CONFORMA THERAPEUTICS CORPORATION 2005-03-03 US disclosed
EP-1440072-A4 PURINE ANALOGS HAVING HSP90-INHIBITING ACTIVITY CONFORMA THERAPEUTIC CORP (US) 2005-02-02 EP disclosed
EP-1440072-A2 PURINE ANALOGS HAVING HSP90-INHIBITING ACTIVITY Conforma Therapeutic Corporation (US) 2004-07-28 EP disclosed
WO-2003037860-A2 PURINE ANALOGS HAVING HSP90-INHIBITING ACTIVITY CONFORMA THERAPEUTICS CORPORATION (US) 2003-05-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080125446-A1 Purine analogs having HSP90-inhibiting activity HSP90B1, HSP90AB1, HSP90AA1 DHFR 448/4885HSP90AA1 3/4885HSP90AB1 2/4885
US-20070129334-A1 Orally Active Purine-Based Inhibitors of Heat Shock Protein 90 HSP90AB1, HSP90AA1, HSP90AB2P DHFR 561/4885HSP90AA1 2/4885HSP90AB1 1/4885
US-20050049263-A1 Purine analogs having hsp90-inhibiting activity HSP90B1, HSP90AB1, HSP90AA1 DHFR 448/4885HSP90AA1 3/4885HSP90AB1 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.